Overview

Phase I/II Study of SY-1425 (Tamibarotene) in Combination With Azacitidine and Venetoclax for Patients With Chronic Myelomonocytic Leukemia

Status:
Withdrawn

Trial end date:
2023-10-20

Target enrollment:

Participant gender:

Summary

To learn if adding venetoclax to the chemotherapy combination of tamibarotene and azacitidine is more effective than tamibarotene and azacitidine alone in treating higher-risk CMM

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Collaborator:

Syros Pharmaceuticals Inc.

Treatments:

Azacitidine
Venetoclax